| Nome |
# |
|
Longterm clinical outcomes in 420 patients with psoriatic arthritis taking anti-tumor necrosis factor drugs in real-world settings, file dd9e0c6b-2d1c-1e9c-e053-3a05fe0a45ef
|
95
|
|
Lipids and atherogenic indices fluctuation in rheumatoid arthritis patients on long-term tocilizumab treatment, file dd9e0c65-8eba-1e9c-e053-3a05fe0a45ef
|
71
|
|
Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases, file dd9e0c65-a994-1e9c-e053-3a05fe0a45ef
|
69
|
|
Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors, file dd9e0c65-6832-1e9c-e053-3a05fe0a45ef
|
50
|
|
The role of biosimilars in uveitis: Long-term real-world outcomes of the switch from original to biosimilar TNF-alpha inhibitors, file dd9e0c66-ccad-1e9c-e053-3a05fe0a45ef
|
50
|
|
Safety of Long-Term Biologic Therapy in Rheumatologic Patients With a Previously Resolved Hepatitis B Viral Infection, file dd9e0c6a-d95f-1e9c-e053-3a05fe0a45ef
|
48
|
|
Basic characteristics of adults with periodic fever, aphthous stomatitis, pharyngitis, and adenopathy syndrome in comparison with the typical pediatric expression of disease, file dd9e0c66-54ed-1e9c-e053-3a05fe0a45ef
|
44
|
|
Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: Premises, perils, and perspectives, file dd9e0c66-35c0-1e9c-e053-3a05fe0a45ef
|
43
|
|
Proinflammatory cytokines and antiskin autoantibodies in patients with inherited epidermolysis bullosa, file dd9e0c66-4df6-1e9c-e053-3a05fe0a45ef
|
43
|
|
Pain Processing and Vegetative Dysfunction in Fibromyalgia: A Study by Sympathetic Skin Response and Laser Evoked Potentials, file dd9e0c6a-de3b-1e9c-e053-3a05fe0a45ef
|
42
|
|
Putative role of serum amyloid-A and proinflammatory cytokines as biomarkers for behcet's disease, file dd9e0c66-4df4-1e9c-e053-3a05fe0a45ef
|
41
|
|
Correlation between serum amyloid-A and serum levels of proinflammatory cytokines in patients with Behçet's disease, file dd9e0c66-4dec-1e9c-e053-3a05fe0a45ef
|
40
|
|
Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives, file dd9e0c65-5b9e-1e9c-e053-3a05fe0a45ef
|
38
|
|
Intravitreal Dexamethasone Implant as an Adjunct Weapon for Severe and Refractory Uveitis in Behçet's Disease, file dd9e0c64-9a02-1e9c-e053-3a05fe0a45ef
|
13
|
|
Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study, file dd9e0c64-a6a0-1e9c-e053-3a05fe0a45ef
|
11
|
|
Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study., file dd9e0c63-b5c8-1e9c-e053-3a05fe0a45ef
|
10
|
|
Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis, file dd9e0c6a-946b-1e9c-e053-3a05fe0a45ef
|
6
|
|
null, file dd9e0c64-c6c8-1e9c-e053-3a05fe0a45ef
|
3
|
|
Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers, file dd9e0c65-6759-1e9c-e053-3a05fe0a45ef
|
3
|
|
null, file dd9e0c66-9972-1e9c-e053-3a05fe0a45ef
|
3
|
|
Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behçet's disease, file dd9e0c67-8816-1e9c-e053-3a05fe0a45ef
|
3
|
|
Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Scleritis, file dd9e0c6c-07bc-1e9c-e053-3a05fe0a45ef
|
3
|
|
Genetic and clinical features of Familial Mediterranean Fever (FMF) in a homogeneous cohort of patients from south-eastern Italy, file 82d46104-afab-4ab3-ac9a-3fc98fe368bc
|
2
|
|
Certolizumab Pegol treatment in Behcet's disease with different organ involvement: A multicenter retrospective observational study, file dd9e0c64-9f5d-1e9c-e053-3a05fe0a45ef
|
2
|
|
Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: an observational multicentre study, file dd9e0c64-ce6d-1e9c-e053-3a05fe0a45ef
|
2
|
|
Critical regulation of Th17 cell differentiation by serum amyloid-A signalling in Behcet's disease, file dd9e0c65-818c-1e9c-e053-3a05fe0a45ef
|
2
|
|
Influence of changes in cholesterol levels and disease activity on the 10 years cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients, file dd9e0c67-4ec5-1e9c-e053-3a05fe0a45ef
|
2
|
|
null, file dd9e0c6a-3b73-1e9c-e053-3a05fe0a45ef
|
2
|
|
null, file dd9e0c6b-0d44-1e9c-e053-3a05fe0a45ef
|
2
|
|
Autoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditis, file dd9e0c6b-180a-1e9c-e053-3a05fe0a45ef
|
2
|
|
Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Uveitis, file dd9e0c6c-07bf-1e9c-e053-3a05fe0a45ef
|
2
|
|
Unraveling the microbiome-metabolome nexus: a comprehensive study protocol for personalized management of Behḉet’s disease using explainable artificial intelligence, file 00167508-380e-4fa5-94ba-c60ab5e59cb7
|
1
|
|
Derivation and validation of four patient clusters in Still's disease, results from GIRRCS AOSD-study group and AIDA Network Still Disease Registry., file b0508656-92d6-4a9d-933b-622227eb2003
|
1
|
|
Development and implementation of the AIDA International Registry for patients with Behçet's disease, file d4673911-f4a4-42cc-8f21-06ac04c1aa75
|
1
|
|
Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study, file dd9e0c63-e953-1e9c-e053-3a05fe0a45ef
|
1
|
|
null, file dd9e0c63-ebed-1e9c-e053-3a05fe0a45ef
|
1
|
|
Systemic Steroid Sparing Effect of Intravitreal Dexamethasone Implant in Chronic Noninfectious Uveitic Macular Edema, file dd9e0c64-a402-1e9c-e053-3a05fe0a45ef
|
1
|
|
null, file dd9e0c64-c6c5-1e9c-e053-3a05fe0a45ef
|
1
|
|
Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies, file dd9e0c65-4410-1e9c-e053-3a05fe0a45ef
|
1
|
|
Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort study, file dd9e0c65-44e6-1e9c-e053-3a05fe0a45ef
|
1
|
|
Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients, file dd9e0c65-50ef-1e9c-e053-3a05fe0a45ef
|
1
|
|
Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis, file dd9e0c65-8606-1e9c-e053-3a05fe0a45ef
|
1
|
|
Epidemiological profile of non-infectious uveitis from the rheumatologist's perspective: a survey from two tertiary referral centres in Italy, file dd9e0c65-871b-1e9c-e053-3a05fe0a45ef
|
1
|
|
Efficacy of anti-tumour necrosis factor-α monoclonal antibodies in patients with non-infectious anterior uveitis, file dd9e0c65-8720-1e9c-e053-3a05fe0a45ef
|
1
|
|
Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab, file dd9e0c65-a52c-1e9c-e053-3a05fe0a45ef
|
1
|
|
Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings, file dd9e0c65-ebee-1e9c-e053-3a05fe0a45ef
|
1
|
|
Refractory knee giant cell tumor of the synovial membrane treated with intra-articular injection of Infliximab: A case series and review of the literature, file dd9e0c65-f3a2-1e9c-e053-3a05fe0a45ef
|
1
|
|
null, file dd9e0c65-f4b6-1e9c-e053-3a05fe0a45ef
|
1
|
|
IL-6 blockade in the management of non-infectious uveitis, file dd9e0c66-06fb-1e9c-e053-3a05fe0a45ef
|
1
|
|
Management of Small Vessel Vasculitides, file dd9e0c66-1fb1-1e9c-e053-3a05fe0a45ef
|
1
|
|
Paradoxical mucocutaneous flare in a case of Behçet’s disease treated with tocilizumab, file dd9e0c66-2ee9-1e9c-e053-3a05fe0a45ef
|
1
|
|
null, file dd9e0c66-4dfd-1e9c-e053-3a05fe0a45ef
|
1
|
|
Efficacy and Safety of Intravenous Immunoglobulin Treatment in Refractory Behcet's Disease with Different Organ Involvement: A Case Series, file dd9e0c66-4fba-1e9c-e053-3a05fe0a45ef
|
1
|
|
Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study, file dd9e0c66-54f5-1e9c-e053-3a05fe0a45ef
|
1
|
|
Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art, file dd9e0c66-54fd-1e9c-e053-3a05fe0a45ef
|
1
|
|
Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey, file dd9e0c66-f379-1e9c-e053-3a05fe0a45ef
|
1
|
|
Effectiveness of TNF-α blockade in the treatment of refractory non-infectious scleritis: a multicentre study, file dd9e0c67-0d7a-1e9c-e053-3a05fe0a45ef
|
1
|
|
Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study, file dd9e0c67-491f-1e9c-e053-3a05fe0a45ef
|
1
|
|
null, file dd9e0c69-def1-1e9c-e053-3a05fe0a45ef
|
1
|
|
The protean ocular involvement in monogenic autoinflammatory diseases: state of the art, file dd9e0c69-edda-1e9c-e053-3a05fe0a45ef
|
1
|
|
null, file dd9e0c6a-3de1-1e9c-e053-3a05fe0a45ef
|
1
|
|
null, file dd9e0c6a-3df1-1e9c-e053-3a05fe0a45ef
|
1
|
|
null, file dd9e0c6a-3f9e-1e9c-e053-3a05fe0a45ef
|
1
|
|
null, file dd9e0c6a-9bd9-1e9c-e053-3a05fe0a45ef
|
1
|
|
Relapsing Polychondritis: an Update on Pathogenesis, Clinical Features, Diagnostic Tools, and Therapeutic Perspectives, file dd9e0c6a-cb5e-1e9c-e053-3a05fe0a45ef
|
1
|
|
A Bayesian mixed treatment comparison of efficacy of biologics and small molecules in early rheumatoid arthritis, file dd9e0c6a-dfe3-1e9c-e053-3a05fe0a45ef
|
1
|
|
Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate, file dd9e0c6a-f0bc-1e9c-e053-3a05fe0a45ef
|
1
|
|
A comprehensive comparison between pediatric and adult patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenopathy (PFAPA) syndrome, file dd9e0c6a-f49a-1e9c-e053-3a05fe0a45ef
|
1
|
|
Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study, file dd9e0c6a-f6c5-1e9c-e053-3a05fe0a45ef
|
1
|
|
Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease, file dd9e0c6b-13af-1e9c-e053-3a05fe0a45ef
|
1
|
|
PFAPA syndrome and Behçet’s disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists, file dd9e0c6b-179d-1e9c-e053-3a05fe0a45ef
|
1
|
|
Auditory involvement in Behcet’s disease: relationship with demographic, clinical, and therapeutic characteristics, file dd9e0c6b-24fa-1e9c-e053-3a05fe0a45ef
|
1
|
| Totale |
788 |